How Close Is the Moderna Vaccine to Approval? (And What Does That Mean for the Stock?)
Moderna (NASDAQ: MRNA) recently completed its submission to U.S. regulators for the full approval of its coronavirus vaccine. If regulators give Moderna the nod, it will join bigger rival Pfizer (NYSE: PFE) in selling a fully approved vaccine. The U.S. Food and Drug Administration approved Pfizer's vaccine last week. Both companies have been selling their vaccines under Emergency Use Authorization (EUA) since December.
As we eagerly await the FDA's decision, we may be asking ourselves the following questions: How long will it take? And how will it affect Moderna shares? Let's look at some clues that may help us come up with answers.
Image source: Getty Images.
Source Fool.com
